TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurotech International ( (AU:NTI) ) has issued an announcement.
Neurotech International Limited has announced a change in its registered office and principal place of business to a new address in Melbourne, effective immediately. This move is part of the company’s ongoing operational adjustments, potentially enhancing its strategic positioning within the biopharmaceutical industry focused on pediatric neurological disorders.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is primarily working on NTI164, an oral cannabinoid drug therapy, and has conducted successful clinical trials in Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome. Neurotech is also preparing for a clinical trial in spastic cerebral palsy.
Average Trading Volume: 622,495
Technical Sentiment Signal: Sell
Current Market Cap: A$19.94M
Learn more about NTI stock on TipRanks’ Stock Analysis page.